Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage

被引:18
|
作者
Chou, Yi-Sheng [1 ,2 ]
Gau, Jyh-Pyng [1 ,2 ]
Yu, Yuan-Bin [1 ,2 ]
Pai, Jih-Tung [1 ,2 ,3 ]
Hsiao, Liang-Tsai [1 ,2 ]
Liu, Jin-Hwang [1 ,2 ]
Hong, Ying-Chung [1 ,2 ]
Liu, Chun-Yu [1 ,2 ]
Yang, Ching-Fen [2 ,4 ]
Chen, Po-Min [1 ,2 ]
Chiou, Tzeon-Jye [1 ,2 ,5 ]
Tzeng, Cheng-Hwai [1 ,2 ]
机构
[1] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei 112, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan
[3] Natl Yang Ming Univ Hosp, Fac Med, Yilan, Taiwan
[4] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei 112, Taiwan
[5] Taipei Vet Gen Hosp, Dept Med, Div Blood Transfus, Taipei 112, Taiwan
关键词
polycythemia vera; essential thrombocythemia; hemorrhage; risk factor; EFFICACY; PATHOPHYSIOLOGY; CLASSIFICATION; COMPLICATIONS; ACTIVATION; SAFETY;
D O I
10.1111/ejh.12064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Long-term outcomes are favorable for patients with polycythemia vera (PV) and for patients with essential thrombocythemia (ET). However, hemorrhage is a significant cause of morbidity and mortality in those patients. Methods We retrospectively recruited 247 patients who had received a diagnosis of PV (n=101) or ET (n=146) during the period 20012010. Results After a median follow-up period of 36.2months, the cumulative incidence of hemorrhage was 39.6% in patients with PV (6.2% per person-year) and 29.7% in patients with ET (5.9% person-years). Episodes of major bleeding occurred in 9.9% of patients with PV and in 14.4% of patients with ET. Overall survival was significantly shorter among patients with hemorrhage than among those without said complication (P<0.001 for overall patients; P=0.002 for patients with PV; P=0.026 for patients with ET). In the univariate analysis, age 60yr (OR: 4.77, P=0.046) and WBC16x109/L (OR: 4.15, P=0.010) were predictors of hemorrhage in patients with PV, and age 60yr (OR: 3.25, P=0.040), WBC16x109/L (OR: 2.89, P=0.024), albumin <4.0g/dL (OR: 4.10, P=0.002), and splenomegaly (OR: 5.19, P=0.002) were predictors of hemorrhage in patients with ET. Multivariate analysis showed that WBC16x109/L was the only significant risk factor for hemorrhage in patients with PV (OR: 3.51, P=0.026) and that splenomegaly was the only risk factor for hemorrhage in patients with ET (OR: 3.00, P=0.048). Conclusion Leukocytosis in PV and splenomegaly in ET are independent risk factors for hemorrhage.
引用
收藏
页码:228 / 236
页数:9
相关论文
共 50 条
  • [31] \ Erythromelalgia in patients with essential thrombocythemia and polycythemia vera
    Hou, Jennifer L.
    Onajin, Oluwakemi
    Gangat, Naseema
    Davis, Mark D. P.
    Wolanskyj, Alexandra P.
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 715 - 717
  • [32] Updates in the management of polycythemia vera and essential thrombocythemia
    Bose, Prithvirai
    Verstovsek, Srdan
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [33] Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
    De Stefano, Valerio
    Za, Tommaso
    Rossi, Elena
    Vannucchi, Alessandro M.
    Ruggeri, Marco
    Elli, Elena
    Mico, Caterina
    Tieghi, Alessia
    Cacciola, Rossella R.
    Santoro, Cristina
    Gerli, Giancarla
    Vianelli, Nicola
    Guglielmelli, Paola
    Pieri, Lisa
    Scognamiglio, Francesca
    Rodeghiero, Francesco
    Pogliani, Enrico M.
    Finazzi, Guido
    Gugliotta, Luigi
    Marchioli, Roberto
    Leone, Giuseppe
    Barbui, Tiziano
    HAEMATOLOGICA, 2008, 93 (03) : 372 - 380
  • [34] Contemporary approach to essential thrombocythemia and polycythemia vera
    Aruch, Daniel
    Mascarenhas, John
    CURRENT OPINION IN HEMATOLOGY, 2016, 23 (02) : 150 - 160
  • [35] Platelet density in essential thrombocythemia and polycythemia vera
    Järemo, P
    PLATELETS, 1999, 10 (01) : 61 - 63
  • [36] DNA METHYLATION IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
    Santiago, S.
    Miguel, G.
    Enriqueta, A.
    Ana, A.
    Rosa, R.
    Joaquin, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 404 - 404
  • [37] Treatment options for essential thrombocythemia and polycythemia vera
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Pieri, Lisa
    Antonioli, Elisabetta
    Bosi, Alberto
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (01) : 41 - 55
  • [38] New drugs in essential thrombocythemia and polycythemia vera
    Tefferi, A
    Elliott, MA
    Solberg, LA
    Silverstein, MN
    BLOOD REVIEWS, 1997, 11 (01) : 1 - 7
  • [39] MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
    Haider, M.
    Elala, Y. C.
    Gangat, N.
    Hanson, C. A.
    Tefferi, A.
    BLOOD CANCER JOURNAL, 2016, 6 : e487 - e487
  • [40] MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
    M Haider
    Y C Elala
    N Gangat
    C A Hanson
    A Tefferi
    Blood Cancer Journal, 2016, 6 : e487 - e487